KBC Securities - UCB S.A. (UCB) UCB FIRST LOOK: String of positive Ph3 readouts continues into SLE

Report

KBC Securities

Thomas Vranken

UCB FIRST LOOK: String of positive Ph3 readouts continues into SLE

UCB announced positive topline results for the first of two Phase 3 trials for anti-CD40L dapimap in systemic lupus erythematosus (SLE). SLE is a debilitating autoimmune disease, characterized by flares that could lead to organ damage. While we currently do not have topline data yet, dapimap is set to compete against GSK's Benlysta and AstraZeneca's Saphnelo and could eventually reach just below $ 1bn peak sales according to our preliminary analysis. We currently value dapimap at € 1.70 p.s., and reiterate our € 168 TP and Accumulate rating.

24/09/2024 1 EN

Underlying

UCB S.A.

UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.

See profile

BE0003739530 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

ING Financial Markets

Benelux Morning Notes

Ageas: Elevate27, devil in the detail, more with less. Belgian telcos: BASE targeting 25k internet customers by the end of 2024, 250k by 2030. UCB: First successful P3 results in Lupus Erythematosus

10h / 3m 10h / 3m 1 EN

KBC Securities

Morning Notes : AGS BB, AKZAa NA, UCB BB, AZE BB, SHUR BB

: AGS BB, AKZAa NA, UCB BB, AZE BB, SHUR BB

10h / 26m 10h / 26m 1 EN

Barco We took ‘One Look' at Barco an decided to lower the barrier

In 1H24, Barco's business was impacted by customer destocking in the Meeting Experience and Healthcare segments. In Entertainment, customers delayed investments as a result of a weak film slate and in anticipation of Barco's upcoming product launches. While visibility remains low, Barco has reason to look forward to a very different 2H24. But we now think it will be even more back-end loaded and somewhat milder than we originally expected. We maintain our positive stance - albeit with a slightly lower Target Price of €15.8 (average of our DCF and SOTP) - as Barco continues to invest in its i...

9h / 27m 9h / 27m 1 EN

Thibault Leneeuw

Thibault Leneeuw

Azelis Never change a winning formula, keep innovating

In this note we go in detail over our takeaways of the site visit in Istanbul and adjust our numbers accordingly. As expected, no new guidance was provided. A logical assumption based on remarks from mgmt., is 4% revenue growth and an increase in EBITA margin of at least 10bp annually. The event was well attended and we left with a positive feeling. We expect less operational leverage on the Gross profit margin, more leverage on the operating expenses and benefits from M&A. We reiterate our Buy rating and increase our target price from € 26 to € 28.

10h / 23m 10h / 23m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

UCB FIRST LOOK: String of positive Ph3 readouts continues into SLE

We are a financial services provider for several types of professional clients, each with distinct needs.

Benelux Morning Notes

Morning Notes : AGS BB, AKZAa NA, UCB BB, AZE BB, SHUR BB

Barco We took ‘One Look' at Barco an decided to lower the barrier

Azelis Never change a winning formula, keep innovating

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe